Skip to main content

Price War in the US and EU

From the series Industry and pharmaceuticals

The contention in the biopharmaceutical field between the two sides of the Atlantic addresses the issue of costs, in two different ways. In a letter to the Financial Times published on April 23rd, Vas Narasimhan and Paul Hudson, the CEOs of Swiss company Novartis and French company Sanofi respectively, presented a harsh diagnosis of the state of European biopharmaceuticals compared to their major competitors, the United States and China. Narasimhan, an American son of immigrants from Tamil Nadu, and Hudson, a Briton, head two of the world's ten largest pharmaceutical multinationals. The two executives see "a strong outlook for the US – thanks to policies and regulations conducive to fast and broad patient access to innovative medicines". In contrast, Europe, "while home to some of the most important biopharma companies in the world", risks decline. "Against a backdrop of waning European biopharma competitiveness, the uncertainty of tariffs is further reducing incentives to invest in the EU". Furthermore, "in the new world context, Europe's pharmaceutical model of producing in Europe and exporting to the US cannot continue. It needs to strengthen its domestic market". They note that in recent weeks biopharmaceutical companies have announced investments in the US of over $150 billion, while there have been no such plans in Europe.

The view from Europe

"Europe's largest issue is failing to properly value innovation", according to Narasimhan and Hudson. "European price controls and austerity measures reduce the attractiveness of its markets. Launch prices are suppressed, patented medicines' growth capped, and prices reduced when new applications are found". As a result, more than 30% of medicines authorised in the United States were still not available in the European Union after two years. The US and China encourage innovation, while Europe penalises it: "Over time it is inevitable that clinical trials and R&D will further shift to the US and China". The CEOs of more than 30 pharmaceutical companies (including US companies) operating in Europe have urged European Commission President Ursula von der Leyen to introduce measures to compensate for the costs of innovation and deliver "radical policy change" in pharmaceuticals [Reuters, April 15th]. The "major European pharmaceutical reform" currently being finalised by the Commission has also attracted criticism, particularly the planned changes to intellectual property protections. For the EFPIA (European Federation of Pharmaceutical Industries and Associations), it is "a missed opportunity to position Europe's life-sciences sector at the forefront of global competition" [If Sale 24 Orc, June 10th]. Novartis and Sanofi are calling on the European Commission and European States for greater price liberalisation and incentives for investment in innovation to make their markets more attractive. Without deregulation, they write, European decline is inevitable.

According to research by the non-profit organisation RAND, based on 2022 data, the gross prices of prescription drugs (or "ethical" drugs) in the United States are on average almost three times higher than those in other OECD countries. RAND considers gross manufacturer prices because the final cost, after various discounts applied by companies along the distribution chain to wholesalers, pharmaceutical managers, health insurers, hospitals, and pharmacies, is not always known. Even taking into account estimated discounts, however, average prices remain three times higher than the OECD average [RAND, International Prescription Drug Price Comparison, 2024].

The view from America

The Trump administration brandished this figure in its May 12th executive order, which announced an "aggressive" plan "to bring prices for American patients and taxpayers in line with comparably developed nations". In reality, not all prescription drugs cost more in the United States. According to RAND, the average price of brand-name drugs is more than four times higher than in OECD countries, but generic products, where competition is fiercer, cost a third less (67%). Generic drugs account for 90% of prescriptions in the US, compared to an average of 41% in the other OECD countries considered.

In the executive order, the White House accuses manufacturers of offering discounted prices "to access foreign markets and [subsidising] that decrease through enormously high prices in the United States". The United States is "subsidising drug-manufacturer profits and foreign health systems". The world benefits from American research supported by "generous subsidies".

Under the order, the Department of Health is tasked with setting "price targets" to be negotiated with companies, based on prices in other countries, according to the "most favoured nation" principle. In the event of non-compliance, the order threatens rules imposing reductions and other "aggressive action" such as importing from countries with better prices.

The issue of drug prices is a long-standing one in the US. In Europe, where single-payer healthcare systems prevail, prices are negotiated by government agencies, which have strong bargaining power with regards to companies. In the US, manufacturers set list prices and then negotiate discounts with insurance companies, hospitals, and intermediaries such as Pharmacy Benefit Managers (PBMs).

Towards the end of his first term, Donald Trump had already tried unsuccessfully to impose a price cut on 50 drugs. In 2022, with the Inflation Reduction Act (IRA), then-President Joe Biden shook up the pharmaceutical market by allowing Medicare, the federal healthcare programme for the elderly, to negotiate prices directly with pharmaceutical companies, which had previously been explicitly prohibited. The following year, the Biden administration released a list of the first ten drugs targeted by the new policy, and in 2024, amidst a presidential election campaign that included healthcare spending as one of its main issues, Biden and candidate Kamala Harris announced a "historic" agreement with drug companies that will take effect in 2026 unless cancelled. The cut will average 25%, and the Congressional Budget Office has estimated that Medicare will save $100 billion over a decade [Financial Times, March 20th, 2023].

Regulation or market

The reforms contained in the IRA had to overcome fierce opposition from multinational pharmaceutical companies, which argued that a price cap would discourage investment in the research and development of new medicines. Six Big Pharma companies from three continents sued the Biden administration on several grounds, including violation of the First Amendment for "the taking of private property for public use without just compensation" [The New York Times, August 29th, 2023]. The US companies Merck, Bristol-Myers Squibb and Johnson & Johnson, Japan's Astellas Pharma, Britain's AstraZeneca and Germany's Boehringer Ingelheim were also supported by the Chamber of Commerce and the PhRMA (Pharmaceutical Research and Manufacturers of America) lobby.

President Trump's current executive order, on the other hand, has so far elicited a "lukewarm" response from companies, which are sceptical about its practical implementation. According to legal and health policy experts quoted by the British Medical Journal, "the executive order reads more like an aspirational statement than a serious attempt to initiate a policy change". The "legal powers" to impose a price-control mechanism not provided for by Congress (traditionally resistant to regulatory interference, especially on the Republican side) are being questioned. Legal disputes are on the horizon. A more likely scenario is "isolated price reductions" through voluntary negotiations [BMI, "Can Trump Really Lower US Drug Prices and Raise Them in Other Countries? Probably Not", June 6th, 2025].

The order seems to be more aimed at intermediaries such as PBMs, big groups that negotiate with companies on behalf of insurers and hospitals. This criticism is shared by the drug companies, which add a dose of protectionism. In a May 12th statement on the order, PhRMA President Stephen J. Ubl said that the "real reasons" prices in the US are higher are "foreign countries not paying their fair share and middlemen driving up prices for US patients. The administration is right to use trade negotiations to force foreign governments to pay their fair share for drugs. US patients should not foot the bill for global innovation".

Between competition and opportunity

For any State, it is a question of public spending, which weighs heavily in the confrontation between powers. Imperialist metropolises are struggling to bear the costs of healthcare. New equipment and increasingly promising – but also more expensive – diagnostic and therapeutic methods are challenging the sustainability of national budgets. Life-sciences companies, on the other hand, are engaged in international competition based on their capacity for innovation.

The rise of China looms over the United States and Europe. According to Narasimhan and Hudson, "China, now the second largest biopharma market, has expanded its position by attracting multinationals and creating a vibrant biotechnology environment". A 2023 European Commission analysis of the 2,500 companies worldwide with the highest R&D expenditure found that 12% of the companies investing the most in health research are based in Europe, compared with 55% in the US and 17% in China [Financial Times, April 26th, 2024].

In medical biotechnology, Chinese companies have produced many promising new molecules, but these require further development to an advanced stage and investment that Chinese companies lack. Western groups, primarily European ones, offer the necessary capital and guarantee marketing licences outside China. Chinese biotech companies have signed 98 cross-border licensing agreements worth around $60 billion. In the first quarter of this year, there were 33 agreements worth $36.2 billion. The "new frontier" of Chinese biotechnology is a challenge for Western groups, but is also an opportunity.

Lotta Commisita, July-August 2025

Labels:

Popular posts from this blog

Cryptocurrencies, Tariffs, Oil and Spending in Trump’s Executive Orders

Internationalism No. 73, March 2025 Page 8 Douglas Irwin, economist and historian of American trade policy, writes for the Peterson Institute that the tariffs announced by Donald Trump, if implemented, would constitute a “historic event in the annals of US trade policy” and “one of the largest increases in trade taxes in US history. One has to go back almost a century to find tariff increases comparable”. Irwin limits himself to providing us with a historical dimension to the planned duties. But the bewilderment and turmoil created, especially among Washington’s allies, derives from the fact that the tariffs being brandished are accompanied by a hail of presidential decrees and declarations that mark a profound political discontinuity, both in the balance of internal institutional powers and in the balance of power between nations. The watershed was expected, but the speed and vehemence of the White House’s assaults are setting the scene for a change of era i...
Read more

The future of work in Europe

Every moment of transition presents its own complexities: for our class this means that further divisions are sown within it. Such is the present moment — one when different dynamics stack up and intertwine. Past, present and future On the one hand, there is the troubled exit from the pandemic crisis, still under the threat posed by the emergence of new Covid-19 variants. The pause on redundancies has come to an end in Italy. This, albeit partially, would have spared about 520,000 jobs in Italy up until now, according to Centro Einaudi’s estimates [ 25 th Annual Report on Global Economy and Italy , June 2021]. Company closures and staff reductions (in a mixture of arrogance and callousness) have marked the summer months, only to announce a difficult autumn, when the redundancy ban will be lifted also for small businesses and services. However, it is clear how uncertain the workers’ condition remains, regardless of any collective agreement signed, and how necessary it is always to ...
Read more

Marx’s Logic

Internationalism No. 73, March 2025 Page 7 From the series Principles of Marxism The method of exposition in Marx’s economic analysis, which he summarised on various occasions, adopts the progression from the simplest to the most complex concepts. It is a method that, at first glance, appears to correspond to common sense — from easy to difficult — but which Marx explains by contradicting common sense. Common sense distorts knowledge, starting right from the elementary building blocks of the representation of reality, which requires scientific abstraction to understand. Opportunism will always set the prejudices of common sense against the science-party . Marx writes, introducing Volume I of Capital : “The value-form , whose fully developed shape is the money-form , is very elementary and simple. Nevertheless, the human mind has for more than 2,000 years sought in vain to get to the bottom of it, whilst on the other hand, to the successful analysis of ...
Read more

Uneven Development, Job Cuts, and the Crisis of Labour Under Global Capitalism

Internationalism No. 73, March 2025 Page 16 Uneven development is a fundamental law of capitalism. We have a macroscopic expression of this in the changing balance of power between States: Atlantic decline and Asian rise are the key dynamics behind the political processes of this era, including wars caused by the crisis in the world order. But behind all this there is a differentiated economic trend, starting from companies and sectors: hence the differentiated conditions for wage earners. And this is the element to keep in mind for an effective defensive struggle. It’s only the beginning The electrical and digital restructuring imposed by global market competition affects various production sectors. The car industry is the most obvious, due to the familiarity of the companies and brands involved. We have already reported on the agreement reached before Christmas at Volkswagen, which can be summarised as a reduction of 35,000 employees by 2030. Die Zeit [De...
Read more

The SPD Faces the War

Internationalism No. 73, March 2025 Page 6 From the series Pages from the history of the worker’s movement The mystification of the First World War as a defensive war was accompanied by a misunderstanding of political forms, i.e., the illusion that the struggle for a democratic national shell was already a struggle against the imperialist content of German power, as if a democracy could exist outside of or above classes. Arrigo Cervetto, in The Political Shell, spoke of “the illusion of the primacy of politics”. At the same time, however, he emphasised the dialectic between structure and superstructure: “The basic view that political power relations depend on economic relations enables the revolutionary movement to overcome the obstacle of self-delusion; on the other hand, this view remains only a general idea if it does not inspire a restless and specific analysis of the situation, and if it does not demand an attitude consequent upon this analysis”. Mar...
Read more

Class Consciousness and Crisis in the World Order

Internationalism No. 71, January 2025 Pages 1 and 2 The consciousness of the proletariat “cannot be genuine class-consciousness, unless the workers learn, from concrete, and above all from topical, political facts and events to observe every other social class in all the manifestations of its intellectual, ethical, and political life; unless they learn to apply in practice the materialist analysis and the materialist estimate of all aspects of the life and activity of all classes, strata, and groups of the population”. If it concentrates exclusively “or even mainly” upon itself alone, the proletariat cannot be revolutionary, “for the self-knowledge of the working class is indissolubly bound up, not solely with a fully clear theoretical understanding or rather, not so much with the theoretical, as with the practical, understanding — of the relationships between all the various classes of modern society”. For this reason, the worker “must have a clear picture in ...
Read more

Engels in the New Century

Friedrich Engels memorably describes the poor sanitary condition of working-class neighbourhoods in mid-19 th century England. At a certain point, typhus and cholera epidemics began to threaten bourgeois neighbourhoods, and only then was the government forced to take remedial action. Well, with the pandemic of the century , it is as if Engels had entered the 21 st century, and the same contradiction was laid bare for the whole world. The Covid-19 catastrophe in India shows an elementary truth: Europe, America and China are completing colossal vaccination plans, but they will never be truly safe if the rest of the world, in Asia, Africa and Latin America, remains at the mercy of the virus and its mutations. And yet, even in the face of the evidence, the contention between powers to take advantage of vaccine diplomacy does not cease. The United States has put forward the promotional idea of suspending the patents of the pharmaceutical giants, perhaps in order to counter the Chinese off...
Read more

Political Battles of European Leninism

Internationalism No. 73, March 2025 Page 1 Thirty years after the death of Arrigo Cervetto , we are publishing here the concluding passages of the introduction to his Opere Scelte (“Selected Works”) for the series Biblioteca Giovani (“Publications for young people”), soon to be published in Italian. The 1944-45 partisan war in Italy. The political battle within libertarian communism. The Korean War, and the watchword of “neither Washington nor Moscow”. The layoffs at the Ilva and Ansaldo factories, the political battle and trade union defence in the struggles of post-war restructuring. From 1953 onwards, the crisis of Stalinism, the 1956 Suez crisis, the Hungarian uprising, the 1957 Theses and the challenge of theory and strategy vis-à-vis the tendencies of unitary imperialism. The political struggle within Azione Comunista (“Communist Action”) and the Movimento della Sinistra Comunista (“Movement of the Communist Left”). From the 1950s to the early 1970s, t...
Read more

States and Courts Counterbalance Trump

Internationalism No. 73, March 2025 Page 10 From the series Chronicles of the new American nationalism Donald Trump’s political agenda has been dictated by the tempo of the dozens of executive orders, memoranda, and proclamations he has signed, challenging international partners abroad, and Congress, the States of the Union, and the bureaucracy at home. The execution of some orders has already been temporarily suspended by federal judges, while the chaos caused by a memorandum led the administration itself to withdraw it. Other rulings are expected from the courts at the request of citizens, NGOs, and States. Furthermore, as James Politi of the Financial Times notes, “the result of his political success” in the elections is that Trump will have to satisfy “a much more diverse political coalition” than in his first term. Ross Douthat, a conservative commentator for The New York Times , also believes that “at least until the Democratic Party gets up off th...
Read more

The Drone War

Internationalism No. 78-79, August-September 2025 Page 13 From the series War industry and European defence The Economist provides an illustration of how the use of unmanned and remotely piloted systems in warfare is expanding. In Africa, 30 governments are equipped with UAVs (unmanned aerial vehicles), or drones. In 2024, they were deployed 484 times in local wars in thirteen different countries, twice as frequently as the previous year, causing 1,200 deaths. The most widely used drone on the continent is the TB2, produced by the Turkish company Baykar, which has seen a decade of extensive use in conflicts across Syria, Azerbaijan-Armenia, and Ukraine. LBA Systems and MALE drones At the Paris Air Show in mid-June, an agreement was signed to establish LBA Systems, a joint venture between Baykar and Leonardo. The aim is to produce the Akinci and TB3 drones, the latter of which will be capable of taking off from helicopter carrier decks. The aircraft wil...
Read more